Key facts
- Rinascera Therapeutics’s last known valuation is $5.0M (Oct 2025).
- It has raised $2.5M across 1 recorded rounds; the latest was Seed Round ($2.5M) in Sep 2025.
- Notable investors include Double Point Ventures.
- Rinascera Therapeutics has filed 1 Form D with the SEC, most recently Oct 2025 ($2.5M sold to 3 investors).
- Status: Privately Held (backing).
Investors
1Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Rinascera Therapeutics
Create free account
No card required
Funding rounds
1 roundsAbout Rinascera Therapeutics
The company is currently operating in stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- Boston, MA, United States
- Founded
- 2025
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Rinascera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Rinascera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Rinascera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.